Evidence map›Paper›PMID 41068839›Full record

ReviewStem cell research & therapy2025

Stem cell therapy for myocardial infarction and atherosclerosis: mechanisms, challenges, and future directions.

Xingchen Wan, Chenyan Qian, Siyi Liu, Yue Xu, Jinghua Yuan, Xinling Zhang, Xiaoping Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xingchen Wan *Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, 310015, P. R. China.
Chenyan Qian *Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, 310015, P. R. China.
Siyi Liu *Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, 310015, P. R. China.
Yue XuKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, 310015, P. R. China.
Jinghua YuanKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, 310015, P. R. China.
Xinling ZhangKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, 310015, P. R. China. Xinlingz_201803@zjsru.edu.cn.
Xiaoping LiKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, 310015, P. R. China. li-xp@zjsru.edu.cn.

Funding

Zhejiang Shuren University Basic Scientific Research Special Funds 2024XZ011
6 · The paper itself

Abstract

Myocardial infarction (MI) and atherosclerosis (AS) are the deadliest category of diseases globally. Preliminary clinical and preclinical studies have shown that stem cell therapy can alleviate symptoms; however, it has not yet achieved full functional regeneration of myocardial or vascular tissues. Stem cell therapy has shown the ability to reverse pathological processes through tissue repair, angiogenesis, and immune modulation. The main challenges of clinical translation remain the low survival rate and uncontrolled differentiation after stem cell transplantation. This paper systematically describes the classification, characteristics, and mechanisms of action of stem cells, as well as the pathological features of MI and AS and the limitations of traditional therapy. It discusses the challenges and solutions for the clinical translation of stem cell therapy. Such advances are expected to promote the development of precise, intelligent, and systematic stem cell therapies for MI and AS. This is very useful for creating multidisciplinary innovation systems in the future.

Indexed as

AtherosclerosisMyocardial InfarctionStem CellsStem Cell TransplantationAnimalsCell DifferentiationHumansAtherosclerosisCardiac stem cellsEmbryonic stem cellsInduced pluripotent stem cellsMesenchymal stem cellsMyocardial infarctionRegenerative medicineStem cell therapy

Identifiers

PMID41068839
PMCPMC12512856

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.